CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer

References

• Smyth E, Lagergren J, Fitzgerald R, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3(1):17048. doi:10.1038/nrdp.2017.48
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang P, Pang Q. Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review. Annals of Translational Medicine. 2020;8(18):1193–1193.
   Web of Science ®Google Scholar
• Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surgery today. 2020;50(1):12–20.
   PubMed Web of Science ®Google Scholar
• Sohda M, Kuwano H. Current status and future prospects for esophageal cancer treatment. Ann Thorac Cardiovasc Surg. 2017;23(1):1–11. doi:10.5761/atcs.ra.16-00162
   PubMed Web of Science ®Google Scholar
• Dröge L, Karras P, Guhlich M, et al. Preoperative radiochemotherapy in esophageal squamous cell cancer with 5-fluorouracil/cisplatin or carboplatin/paclitaxel: treatment practice over a 20-year period and implications for the individual treatment modalities. Cancers. 2021;13(8):1834. doi:10.3390/cancers13081834
   PubMed Web of Science ®Google Scholar
• Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. Mol Cancer. 2018;17(1):25. doi:10.1186/s12943-018-0775-3
   PubMed Web of Science ®Google Scholar
• Däster S, Eppenberger-Castori S, Mele V, et al. Low expression of programmed death 1 (PD-1), PD-1 ligand 1 (PD-L1), and low CD8+ T lymphocyte infiltration identify a subgroup of patients with gastric and esophageal adenocarcinoma with severe prognosis. Front Med. 2020;7:144. doi:10.3389/fmed.2020.00144
   Web of Science ®Google Scholar
• Chen J, Luo S, Qin S, et al. Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: analysis of the Chinese subgroup in KEYNOTE-181. Ann Oncol. 2019;30:v294.
   Google Scholar
• Kim H, Hong J, Lee J, et al. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Therapeutic advances in medical oncology. 2021;13:1758835921992992.
   Web of Science ®Google Scholar
• Chan T, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi:10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Chalmers Z, Connelly C, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Goodman A, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Milano F, Rygiel AM, Buttar N. An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. Cancer Immunol Immunother. 2007;56(12):1967–1977. doi:10.1007/s00262-007-0341-0
   PubMed Web of Science ®Google Scholar
• Yu X, Teng Y, Jiang X, Yuan H, Jiang W. Genome-wide DNA methylation pattern of cancer stem cells in esophageal cancer. Technol Cancer Res Treat. 2020;19:1533033820983793. doi:10.1177/1533033820983793
   Web of Science ®Google Scholar
• Das P, Islam F, Smith R, Lam A. Therapeutic strategies against cancer stem cells in esophageal carcinomas. Front Oncol. 2020;10:598957. doi:10.3389/fonc.2020.598957
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang X, Wang N, et al. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis. Life Sci. 2021;277:119505. doi:10.1016/j.lfs.2021.119505
   PubMed Web of Science ®Google Scholar
• Panja S, Hayati S, Epsi N, Parrott J, Mitrofanova A. Integrative (epi) genomic analysis to predict response to androgen-deprivation therapy in prostate cancer. EBioMedicine. 2018;31:110–121. doi:10.1016/j.ebiom.2018.04.007
   PubMed Web of Science ®Google Scholar
• Newman A, Steen C, Liu C, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–782. doi:10.1038/s41587-019-0114-2
   PubMed Web of Science ®Google Scholar
• Malta T, Sokolov A, Gentles A, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338–354.e315.
   PubMed Web of Science ®Google Scholar
• Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(D1):D955–D961. doi:10.1093/nar/gks1111
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56.
   PubMed Web of Science ®Google Scholar
• Woo S, Corrales L, Gajewski T. Innate immune recognition of cancer. Annual review of immunology. 2015;33:445–474.
   PubMed Web of Science ®Google Scholar
• Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. Innate immune signaling and regulation in cancer immunotherapy. Cell Research. 2017;27(1):96.
   PubMed Web of Science ®Google Scholar
• Sun P, Uppaluri R, Schmidt A, et al. Transcript map of the 8p23 putative tumor suppressor region. Genomics. 2001;75(1–3):17–25. doi:10.1006/geno.2001.6587
   PubMed Web of Science ®Google Scholar
• Tang M, Wang Y, Guo S, Han S, Wang D. CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis : an international journal on programmed cell death. 2012;17(9):927–937
   PubMed Web of Science ®Google Scholar
• Zhu Q, Gong L, Wang J, et al. miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC cancer. 2016;16(1):806.
   PubMed Web of Science ®Google Scholar
• Escudero-Esparza A, Bartoschek M, Gialeli C, et al. Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer. Oncotarget. 2016;7(47):76920–76933. doi:10.18632/oncotarget.12729
   PubMedGoogle Scholar
• Tang MR, Wang YX, Guo S, Han SY, Wang D. CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis. 2012;17(9):927–937. doi:10.1007/s10495-012-0727-0
   PubMed Web of Science ®Google Scholar
• Zhang R, Song C. Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. Tumour Biol. 2014;35(5):4419–4423. doi:10.1007/s13277-013-1581-6
   PubMedGoogle Scholar
• Hogan LE, Meyer JA, Yang J, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011;118(19):5218–5226.
   PubMed Web of Science ®Google Scholar
• Toomes C, Jackson A, Maguire K, et al. The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis. Genes Chromosomes Cancer. 2003;37(2):132–140.
   PubMed Web of Science ®Google Scholar
• Bignell G, Greenman C, Davies H, et al. Signatures of mutation and selection in the cancer genome. Nature. 2010;463(7283):893–898.
   PubMed Web of Science ®Google Scholar
• Shull AY, Clendenning ML, Ghoshal-Gupta S, et al. Somatic Mutations, Allele Loss, and DNA Methylation of the Cub and Sushi Multiple Domains 1 (CSMD1) Gene Reveals Association with Early Age of Diagnosis in Colorectal Cancer Patients. Plos One. 2013;8(3):e58731.
   PubMed Web of Science ®Google Scholar
• Shull AY, Clendenning ML, Ghoshal-Gupta S, et al. Somatic mutations, allele loss, and DNA methylation of the Cub and Sushi multiple domains 1 (CSMD1) gene reveals association with early age of diagnosis in colorectal cancer patients. PLoS One. 2013;8(3):e58731. doi:10.1371/journal.pone.0058731
   PubMed Web of Science ®Google Scholar
• Kamal M, Holliday D, Morrison E, Speirs V, Toomes C, Bell S. Loss of CSMD1 expression disrupts mammary duct formation while enhancing proliferation, migration and invasion. Oncol Rep. 2017;38(1):283–292. doi:10.3892/or.2017.5656
   PubMed Web of Science ®Google Scholar
• Ma C, Quesnelle KM, Sparano A, Rao S, Brose MS. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther. 2009;8(10):907–916. doi:10.4161/cbt.8.10.8132
   PubMed Web of Science ®Google Scholar
• Kamal M, Shaaban AM, Zhang L, et al. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Res Treat. 2010;121(3):555–563. doi:10.1007/s10549-009-0500-4
   PubMed Web of Science ®Google Scholar
• Patterns of somatic mutation in human cancer genomes. European Journal of Cancer Supplements. 2007;6(9):153-158. Stratton MR, Futreal PA. Cancer: Understanding the target. Nature. 2004;430(6995):30.
   PubMed Web of Science ®Google Scholar
• Vogeistein, Bert, Kinzler, Kenneth, W. Cancer genes and the pathways they control. Nature Medicine. 2004;10(8):789–799.
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood L, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268–274. doi:10.1126/science.1133427
   PubMed Web of Science ®Google Scholar
• Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Eur J Cancer Suppl. 2007;6(9):153–158.
   Google Scholar
• Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2012;44(2):133–139. doi:10.1038/ng.1026
   Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom D. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67. doi:10.1182/blood-2017-06-741033
   PubMed Web of Science ®Google Scholar
• Beatty G, Li Y, Long K. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17(2):175–186. doi:10.1080/14737140.2017.1270208
   PubMed Web of Science ®Google Scholar
• Sodani K, Patel A, Kathawala RJ, Chen ZS. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer. 2012;31(2):58–72. doi:10.5732/cjc.011.10329
   PubMed Web of Science ®Google Scholar
• Chen Y, Ye J, Zhu Z, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, Phase III clinical trial. J Clin Oncol. 2019;37(20):1695.
   PubMed Web of Science ®Google Scholar
• Zhang X, Jia J, Lu M, et al. Nimotuzumab plus paclitaxel and cisplatin as a 1 st -line treatment for esophageal cancer: long term follow-up of a Phase II study. J Cancer. 2019;10(6):1409–1416. doi:10.7150/jca.28659
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641. doi:10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692–696.
   PubMed Web of Science ®Google Scholar
• Nutt S, Hodgkin P, Tarlinton D, Corcoran L. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160–171. doi:10.1038/nri3795
   PubMed Web of Science ®Google Scholar
• Hollern DP, Xu N, Thennavan A, et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell. 2019;179(5):1191–1206.e1121. doi:10.1016/j.cell.2019.10.028
   PubMed Web of Science ®Google Scholar
• Shi W, Dong L, Sun Q, et al. Follicular helper T cells promote the effector functions of CD8+ T cells via the provision of IL-21, which is downregulated due to PD-1/PD-L1-mediated suppression in colorectal cancer. Exp Cell Res. 2018;372(1):35–42. doi:10.1016/j.yexcr.2018.09.006
   PubMed Web of Science ®Google Scholar
• Ma QY, Huang DY, Zhang HJ, Chen J, Miller W, Chen XF. Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer. Int Immunopharmacol. 2016;41:1–7. doi:10.1016/j.intimp.2016.10.014
   PubMed Web of Science ®Google Scholar
• Goh M, Lim ZM, Koh V, Lum J, Chen J. Single-cell analysis of immune-microenvironment and immune-tumor interaction in human gastric cancers. J Clin Oncol. 2019;37(4_suppl):29. doi:10.1200/JCO.2019.37.4_suppl.29
   Web of Science ®Google Scholar
• Duan J, Deng T, Ying G, et al. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy. Jpn J Clin Oncol. 2016;46(4):336–343. doi:10.1093/jjco/hyv206
   PubMed Web of Science ®Google Scholar
• Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007;178(7):4222–4229. doi:10.4049/jimmunol.178.7.4222
   PubMed Web of Science ®Google Scholar
• Wang J, Huang S, Zhang L, et al. Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma. Cancer Med. 2019;8(3):1315–1325. doi:10.1002/cam4.1894
   PubMed Web of Science ®Google Scholar
• Zheng H, Bai L. Hypoxia induced microRNA-301b-3p overexpression promotes proliferation, migration and invasion of prostate cancer cells by targeting LRP1B. Exp Mol Pathol. 2019;111:104301
   PubMed Web of Science ®Google Scholar
• Beer AG, Zenzmaier C, Schreinlechner M, et al. Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member. Oncotarget. 2016;7(42):68721–68733
   PubMedGoogle Scholar
• Yang M, Yuan Z. A novel role of PRR14 in the regulation of skeletal myogenesis. Cell Death Dis. 2015;6(4):e1734. doi:10.1038/cddis.2015.103
   PubMed Web of Science ®Google Scholar
• Chen X, Cao Y, Sedhom W, et al. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma. Mol Oncol. 2020;14(1):139–158. doi:10.1002/1878-0261.12584
   PubMed Web of Science ®Google Scholar
• Hu J, Zhang X, Wang F, et al. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Oncotarget. 2015;6(42):44643–44659. doi:10.18632/oncotarget.5989
   PubMedGoogle Scholar
• Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007;59(12):752–757. doi:10.1080/15216540701736285
   PubMed Web of Science ®Google Scholar